Agilon Health price target lowered to $27 from $35 at Truist

Truist analyst Jailendra Singh lowered the firm’s price target on Agilon Health (AGL) to $27 from $35 and keeps a Buy rating on the shares. Shares of value-based care names in the firm’s coverage were volatile last week due to utilization commentary made by the two largest Medicare Advantage payers in the market – UnitedHealth (UNH) and Humana (HUM) – the analyst tells investors in a research note. Given the recent uncertainty around utilization and market sentiment, the firm is updating its price target on Agilon, Truist added.